Research and development organization specializing in the field of transplantation therapy for patients with diabetes. Products are sold to multiple industries. The bulk of revenue is derived from activity in the pharmaceuticals industry. This company was capitalized by corporate investment, private investment and venture capital. Stock symbol: MIIS. No international business reported. Products include diabetic agent R&D.